Sep 23, 2020 / 03:00PM GMT
Sara Parigian -
Good day, and welcome to the Cardiff Oncology KOL call on KRAS in clinical practice for colorectal cancer. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Cardiff Oncology website following the conclusion of the event.
I would now like to turn the call over to your host, Dr. Mark Erlander, Chief Executive Officer at Cardiff Oncology.
Please go ahead, sir.
Mark Erlander - Cardiff Oncology, Inc. - Chief Scientific Officer, CEO & Director
Thank you, operator, and good morning to all of you that have joined us today for today's key opinion leader event. Before I begin, I'd like to thank LifeSci Advisors for putting this event together as well as our key opinion leaders, Dr. Afsaneh Barzi and Dr. Heinz-Josef Lenz, for their time.
Today's event will focus on KRAS in colorectal cancer, beginning with a discussion by Dr. Barzi on the history of KRAS in clinical practice, the challenges of drug development and effectively targeting KRAS mutations and the current
Cardiff Oncology, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
